Nested Therapeutics Reports Initial Encouraging Clinical Activity and Favorable Tolerability of NST-628, a Brain-Penetrant Pan-RAF/MEK Molecular Glue, at AACR 2026

38% response rate and 85% disease control rate at recommended dose in advanced/metastatic NRAS and BRAF Class II/III melanoma following failure of standard therapy Responses observed across multiple RAS/MAPK-driven tumors with early evidence of CNS activity Approximately 8,000 NRAS and...